Repligen Corporation with ticker code (RGEN) now have 10 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $225.00 and $155.00 suggesting an average analyst share price target price of $198.48. (at the time of writing). Given that the stocks previous close was at $127.00 this is indicating there is a potential upside of 56.3%. The 50 day moving average now sits at $153.06 and the 200 day moving average is $167.19. The company has a market capitalization of 7.07B. The current share price for the company is: $126.59 USD
The potential market cap would be $11,054,445,459 based on the market consensus.
The company has a dividend yield of 5.38%. Other points of data to note are a P/E ratio of 468.85, revenue per share of $10.89 and a 0.6% return on assets.
Repligen Corporation is a life sciences company, which develops and commercializes bioprocessing technologies and systems that rises flexibility in the process of manufacturing biological drugs. The Company’s bioprocessing business consist of four franchises, filtration; chromatography; process analytics; and proteins. The Filtration products are used in process development and process scale production. The Chromatography franchise includes products used in downstream purification, development, and manufacturing of biological drugs. The Process Analytics products allow end-users to make in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins franchise is represented by its Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all monoclonal antibody (mAb) based drugs on the market.
